Professor

Kathryn Tinckam

Department of Medicine

MD, MMSc, FRCPC, FAST

Location
Toronto General Hospital: University Health Network (UHN)
Address
585 University Ave., Room 11PMB-187, Toronto, Ontario Canada M5G 2N2
Research Interests
Genetics Genomics & Proteomics
Appointment Status
Cross-Appointed

Professional Memberships

  • Secretary of the Canadian Society of Transplantation

Dr Kathryn Tinckam is the Medical Director of the HLA (human leukoantigen) Laboratory and a transplant nephrologist at the University Health Network, and an Associate Professor of Medicine and Laboratory Medicine at the University of Toronto.

She is also Medical Advisor in Transplantation for Canadian Blood Services, responsible for interprovincial listing and allocation and the Canadian Transplant Registry clinical programs, and is the Secretary of the Canadian Society of Transplantation.

She received her undergraduate medical education and Internal Medicine training at the University of Manitoba, her nephrology and transplant training at UBC and completed a fellowship in Histocompatibility and Immunogenetics at Harvard University.

Her clinical and research interests encompass the standardization of HLA laboratory testing, clinical programs to increase transplant in highly sensitized patients, the contribution of HLA antibodies to antibody mediated rejection pathways and outcomes and the management of HLA related alloimmune injury.

 

Research Synopsis

 

My research interests encompass:

  • the standardization of HLA laboratory testing
  • clinical programs to increase transplant in highly sensitized patients
  • the contribution of HLA antibodies to antibody mediated rejection pathways
  • outcomes and the management of HLA related alloimmune injury.

 

Recent Publications

 

Jussi M. Tikkanen, Lianne G. Singer, S. Joseph Kim, Yanhong Li, Matthew Binnie, Cecilia Chaparro, Chung-Wai Chow, Tereza Martinu, Sassan Azad, Shaf Keshavjee, and Kathryn Tinckam. De novo DQ-donor-specific antibodies are associated with chronic lung allograft dysfunction after lung transplantation. American Journal of Respiratory and Critical Care Medicine. 2016 Mar 11;Epub ahead of print as  DOI: 10.1164/rccm.201509-1857OC.

K.J. Tinckam, C.Rose, S. Hariharan, J.S. Gill. Re-examining Risk of Repeated HLA Mismatch in Kidney Transplant. Journal of the American Society of Nephrology. 2016 Feb 17.

K. J. Tinckam, R. Liwski, D. Pochinco, M. Mousseau, A. Grattan, P. Nickerson, P. Campbell. cPRA Increases with DQA, DPA and DPB Unacceptable Antigens in the Canadian cPRA Calculator. American Journal of Transplantation. 2015 Dec;15(12):3194-201.

Chen CK, Manlhiot C, Conway J, Allain-Rooney T,  McCrindle BW, Tinckam K,  Dipchand AI. Development and impact of de novo anti-HLA antibodies in pediatric heart transplant recipients. American Journal of Transplantation. 2015 Aug;15(8):2215-22. doi: 10.1111/ajt.13259.

Ferrari P, Weimar W, Johnson RJ, Lim WH, Tinckam KJ. Kidney paired donation: principles, protocols and programs. Nephrol Dial Transplant. 2015 Aug;30(8):1276-85. pii: gfu309.

A. Konvalinka, K. Tinckam. Utility of HLA Antibody Testing in Kidney Transplantation. Journal of the American Society of Nephrology. 2015 Jul 26;26:1489-1502.

Adriana Luk, Ana Carolina Alba Jagdish Butany,  Kathryn Tinckam MD,Diego Delgado,   Heather J. Ross. C4d immunostaining is an independent predictor of cardiac allograft vasculopathy and death in heart transplant recipients. Transplantation International. 2015 Jul;28(7):857-63.

Sapir-Pichhadze, Ruth; Tinckam, Kathryn;Laupacis, Andreas; Logan, Alexander;Beyene, Joseph; Kim, S. Joseph. Immune Sensitization and Mortality in Wait-listed Kidney Transplant Candidates. Journal of the American Society of Nephrology. 2015 Jun 8. pii: ASN.2014090894.

Kathryn Tinckam, Shaf Keshavjee, Cecilia Chaparro, David Barth, Sassan Azad, Matthew Binnie, Chung-Wai Chow, Marc de Perrot, Andrew F. Pierre, Thomas K. Waddell, Kazuhiro Yasufuku, Marcelo Cypel, Lianne G. Singer. Survival in Sensitized Lung Transplant Recipients with Perioperative Desensitization. American Journal of Transplantation. 2015 Feb;15(2):417-26.

Sapir-Pichhadze R, Curran SP, John R, Tricco AC, Uleryk E, Laupacis A, Tinckam K, Sis B, Beyene J, Logan AG, Kim SJ. A systematic review of the role of C4d in the diagnosis of acute antibody-mediated rejection. Kidney Int. 2015 Jan;87(1):182-94.

Sapir-Pichhadze R, Tinckam K, Quach K, Logan AG, Laupacis A,John R, Beyene J, Kim SJ. HLA-DR and -DQ Eplet mismatches and transplant glomerulopathy: a nested case-control study. American Journal of Transplantation. 2015 Jan;2015(1):137-48.

Alba AC, Tinckam K, Foroutan F, Nelson LM, Gustafsson F, Sander K, Bruunsgaard H, Chih S, Hayes H, Rao V, Delgado D, Ross HJ. Factors associated with anti-human leukocyte antigen antibodies in patients supported with continuous-flow devices and effect on probability of transplant and post-transplant outcomes. J Heart Lung Transplant. 2014 Dec 8: pii: S1053-2498(14)01489-2.

Chih S, Tinckam K, Ross H. A Survey of Current Practice for Antibody Mediated Rejection in Heart Transplantation. American Journal of Transplantation. 2013 Jan 28;13(4):1069-74.

Noone D, Al-Matrafi J, Tinckam K, Zipfel PF, Herzenberg AM, Thorner PS, Pluthero FG, Kahr WH, Filler G, Hebert D, Harvey E, Licht C. Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. American Journal of Transplantation. 2012 Sep;12(9):2546-53. 2012 Sep;12(9):2546-53.

Chih S, Chruscinski A, Ross HJ, Tinckam K, Butany J and Rao V. Antibody-mediated rejection: an evolving entity in heart transplantation. J Transplant. 2012 Mar;2012:Article ID 210210.

 

Appointments

Medical Director, HLA Laboratory, University Health Network
Medical Advisor in Transplantation for Canadian Blood Services